|  |  | 

India Top Headlines

Explained: What is the Recombinant Protein Vaccine? India News

NEW DELHI: Recombinant protein vaccine is another proven method against the deadly Covid-19 virus.
This technology teaches the body how to develop immunity against the new coronavirus by using virus spike proteins.
Used by Novavax in the development of the Covovax vaccine, these vaccines often require the addition of adjuvants to generate a stronger response against the virus.
According to sources, the Serum Institute of India (SII) is likely to launch clinical trials of the Novavax Covid-19 vaccine for children in July.
“The results from Novavax are promising. This vaccine is very safe and very effective. Clinical trials are underway and are in an advanced stage of completion,” said Dr. VK Paul of Niti Aayog.
IBS is likely to introduce the Novavax vaccine into the country in September. This after the vaccine was found to be more than 90 percent effective in clinical trials conducted in the US that involved 29,960 participants.
In phase 3 trials conducted in the USA, NVX-CoV2373 demonstrated 100% protection against moderate and severe disease.
NVX-CoV2373 was created using Novavax’s recombinant nanoparticle technology to generate antigen derived from coronavirus peak (S) protein and is formulated with Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralizing antibodies.
It contains purified protein antigen and cannot replicate or cause Covid-19.
The vaccine can be stored between 2 and 8 degrees Celsius. It is packaged in a ready-to-use liquid formulation in 10-dose vials.
Different pharmaceutical companies have taken different approaches to developing Covid-19 vaccines to stimulate a longer lasting immune system response.

Reference page